Exhibit 99.1
Advanced BioPhotonics Inc. and the Yale University School of Medicine Enter Into
Pilot Site Agreement
BOHEMIA, N.Y.--(BUSINESS WIRE)--Feb. 21, 2006--
Yale University School of Medicine to Serve as a Pilot Site to Test
the Use of Company's DIRI(R) Technology in Plastic Surgery
Applications
Advanced BioPhotonics, Inc. (OTCBB: ABPH) (Frankfurt/FSE: YP2), a
developer of next-generation medical imaging applications using
advanced infrared technology announced today that it has entered into
a pilot site agreement with Yale University School of Medicine's
Department of Surgery. The project will investigate the use of
Advanced BioPhotonics' DIRI(R) brand of dynamic infrared imaging in
mapping vascular perforator vessels and post-op monitoring of flap
viability in reconstructive breast surgery.
"Based on earlier work done at the University of Geneva, the
Company believes that perforator vessel localization represents a very
promising application where we may be able to demonstrate faster and
more accurate vascular assessment," said ▇▇▇▇▇ ▇'▇▇▇▇▇▇, CEO of
Advanced BioPhotonics. "We feel that this application represents a
very important early market for our BioScanIR(R) product and are
delighted to be working with an institution as prestigious as Yale
University School of Medicine in this area."
To conduct this study, which is scheduled to start later this
month, Yale will employ the Company's BioScanIR(R) System, a
functional medical imaging modality that provides a fast,
non-invasive, radiation-free method for detecting diseases that affect
blood perfusion. The agreement is for a period of one year.
About Advanced BioPhotonics
Advanced BioPhotonics Inc., headquartered in Bohemia, New York, is
a leading developer of functional medical imaging applications using
advanced infrared technology for the observation and measurement of
changes of photonic activity within tissue. Advanced BioPhotonics
provides imaging technology for clinicians and researchers for,
disease detection and disease management and drug discovery
applications.
Advanced BioPhotonics' mission is to improve the quality and
cost-effectiveness of healthcare services and research through
identifying, acquiring and adapting high-resolution infrared
technology for biomedical applications. For more information about the
Company and its technology, please visit ▇▇▇▇://▇▇▇.▇▇▇▇▇▇▇▇▇▇.▇▇▇/.
This press release includes statements that may constitute
"forward-looking" statements, usually containing the words "believe,"
"estimate," "project," "expect" or similar expressions. These
statements are made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements inherently involve risks and uncertainties that could cause
actual results to differ materially from the forward-looking
statements. Factors that would cause or contribute to such differences
include, but are not limited to, continued acceptance of the Company's
products and services in the marketplace, the ability of the Company
to develop effective new products and receive governmental approvals
of such products, competitive factors, dependence upon third-party
vendors, and other risks detailed in the Company's periodic report
filings with the Securities and Exchange Commission. By making these
forward-looking statements, the Company undertakes no obligation to
update these statements for revisions or changes after the date of
this release.
CONTACT: The Investor Relations Group
▇▇▇▇▇ ▇▇▇▇▇, ▇▇▇-▇▇▇-▇▇▇▇
Fax: ▇▇▇-▇▇▇-▇▇▇▇
▇▇▇▇://▇▇▇.▇▇▇▇▇▇▇▇▇▇.▇▇▇